[1]高亮 芦颜美.慢性心力衰竭并发肌少症和恶病质的诊治进展[J].心血管病学进展,2023,(7):598.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.006]
　GAO Liang,LU Yanmei.Diagnosis and Treatment of Chronic Heart Failure Complicated with Sarcopenia and Cachexia[J].Advances in Cardiovascular Diseases,2023,(7):598.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.006]
点击复制

慢性心力衰竭并发肌少症和恶病质的诊治进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年7期
页码:
598
栏目:
综述
出版日期:
2023-07-25

文章信息/Info

Title:
Diagnosis and Treatment of Chronic Heart Failure Complicated with Sarcopenia and Cachexia
作者:
高亮 芦颜美
(新疆医科大学第一附属医院心脏起搏电生理科,新疆 乌鲁木齐 830054 )
Author(s):
GAO Liang; LU Yanmei
(Cardiac Pacing Electrophysiology DepartmentThe First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054,Xinjiang,China)
关键词:
慢性心力衰竭; 肌少症; 恶病质
Keywords:
Chronic heart failure; Sarcopenia; Cachexia
DOI:
10.16806/j.cnki.issn.1004-3934.2023.07.006
摘要:
肌少症和恶病质是慢性心力衰竭常见的并发症。在慢性心力衰竭患者中，心输出量减少和全身充血状态会导致食物摄入量不足、运动能力下降、大量促炎症因子释放、交感神经兴奋性反射性增高、机体免疫激活等一系列病理生理进程，从而导致骨骼肌减少及恶病质。目前的临床研究对治疗这两种综合征有潜在益处的药物包括睾酮、促生长激素释放多肽、重组人生长激素、必需氨基酸和β2肾上腺素能受体激动剂等，另外运动锻炼及营养支持等辅助治疗措施亦被证实有效。现总结慢性心力衰竭患者肌肉减少的病理生理机制，并探讨治疗策略的新进展。
Abstract:
Sarcopenia and cachexia are common complications of chronic heart failure(CHF). In patients with CHF, reduced cardiac output and a state of systemic congestion lead to a series of pathophysiological processes such as inadequate food intake,decreased exercise capacity,massive release of pro-inflammatory factors,reflexive increase in sympathetic excitability,and immune activation of the organism,resulting in skeletal muscle reduction and cachexia. Currently,drugs with potential benefit in clinical studies for the treatment of muscle loss in both syndromes include testosterone,growth hormone-releasing polypeptide,recombinant human growth hormone,essential amino acids,and β2-adrenergic receptor agonists,in addition to adjuvant therapeutic measures such as exercise and nutritional support,which have also been shown to be effective. This article summarizes the pathophysiological mechanisms of muscle loss in CHF patients and discuss new advances in treatment strategies.——————基金项目：新疆维吾尔自治区青年科技拔尖人才项目（2022TSYCCX0101）通信作者：芦颜美，E-mail: gracy@189.cn

参考文献/References:

[1] Thanapholsart J,Khan E,Ismail TF,et al. The complex pathophysiology of cardiac cachexia:a review of current pathophysiology and implications for clinical practice[J]. Am J Med Sci,2023,365(1):9-18.
[2] Zuo X,Li X,Tang K,et al. Sarcopenia and cardiovascular diseases:a systematic review and meta-analysis[J]. J Cachexia Sarcopenia Muscle,2023 Apr 1. DOI: 10.1002/jcsm.13221. Epub ahead of print.
[3] Lena A,Anker MS,Springer J. Muscle wasting and sarcopenia in heart failure—The current state of science[J]. Int J Mol Sci,2020,21(18):6549.
[4] Drescher C,Konishi M,Ebner N,et al. Loss of muscle mass:current developments in cachexia and sarcopenia focused on biomarkers and treatment[J]. J Cachexia Sarcopenia Muscle,2015,6(4):303-311.
[5] Yamamoto K,Takeshita H,Rakugi H. ACE2,angiotensin 1-7 and skeletal muscle:review in the era of COVID-19[J]. Clin Sci,2020,134(22):3047-3062.
[6] Oh S,Yang JY,Park CH,et al. Dieckol reduces muscle atrophy by modulating angiotensin type Ⅱ type 1 receptor and NADPH oxidase in spontaneously hypertensive rats[J]. Antioxidants(Basel),2021,10(10):1561.
[7] von Haehling S,Ebner N,Dos Santos MR,et al. Muscle wasting and cachexia in heart failure:mechanisms and therapies[J]. Nat Rev Cardiol,2017,14(6):323-341.
[8] Prokopidis K,Isanejad M,Akpan A,et al. Exercise and nutritional interventions on sarcopenia and frailty in heart failure:a narrative review of systematic reviews and meta-analyses[J]. ESC Heart Fail,2022,9(5):2787-2799.
[9] Loncar G,Springer J,Anker M,et al. Cardiac cachexia:hic et nunc[J]. J Cachexia Sarcopenia Muscle,2016,7(3):246-260.
[10] Li Y,Li S,Wu H.? Ubiquitination-proteasome system(UPS) and autophagy two main protein degradation machineries in response to cell stress[J]. Cells,2022,11(5):851.
[11] Morley JE. Pharmacologic options for the treatment of sarcopenia[J]. Calcif Tissue Int,2016,98(4):319-333.
[12] Martins T,Vitorino R,Moreira-Gon?alves D,et al. Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia[J]. Clin Biochem,2014,47(1-2):8-15.
[13] Kamo T,Akazawa H,Suzuki JI,et al. Novel concept of a heart-gut axis in the pathophysiology of heart failure[J]. Korean Circ J,2017,47(5):663-669.
[14] Potes Y,de Luxán-Delgado B,Rodriguez-González S,et al. Overweight in elderly people induces impaired autophagy in skeletal muscle[J]. Free Radic Biol Med,2017,110:31-41.
[15] Krysztofiak H,Wleklik M,Migaj J,et al. Cardiac cachexia:a well-known but challenging complication of heart failure[J]. Clin Interv Aging,2020,15:2041-2051.
[16] Cruz-Jentoft AJ,Baeyens JP,Bauer JM,et al. Sarcopenia:European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in Older People[J]. Age Ageing,2010,39(4):412-423.
[17] 崔华,王朝晖,吴剑卿,等. 老年人肌少症防控干预中国专家共识(2023)[J]. 中华老年医学杂志,2023,42(2):144-153.
[18] Raj L,Adhyaru B.? An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction(HFrEF)[J]. Postgrad Med J,2016,92(1094):726-734.
[19] Yin J,Lu X,Qian Z,et al. New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure[J]. Theranostics,2019,9(14):4019-4029.
[20] Bielecka-Dabrowa A,Godoy B,Suzuki T,et al. Subclinical hypothyroidism and the development of heart failure:an overview of risk and effects on cardiac function[J]. Clin Res Cardiol,2019,108(3):225-233.
[21] Willis MS,Parry TL,Brown DI,et al. Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1[J]. Circ Heart Fail,2019,12(3):e005234.
[22] Peris-Moreno D,Taillandier D,Polge C. MuRF1/TRIM63,master regulator of muscle mass[J]. Int J Mol Sci,2020,21(18):6663.
[23] Alcazar J,Frandsen U,Prokhorova T,et al. Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power:the Copenhagen Sarcopenia Study[J]. J Cachexia Sarcopenia Muscle,2021,12(6):1418-1427.
[24] Gruber KA,Ji RL,Gallazzi F,et al. Development of a therapeutic peptide for cachexia suggests a platform approach for drug-like peptides[J]. ACS Pharmacol Transl Sci,2022,5(5):344-361.
[25] Scott RA,Callisaya ML,Duque G,et al. Assistive technologies to overcome sarcopenia in ageing[J]. Maturitas,2018,112:78-84.

相似文献/References:

[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
　DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(7):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
　ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(7):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
　TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[4]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
　HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(7):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[5]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
　GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(7):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[6]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
　MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(7):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[7]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
　GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(7):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
[8]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
　WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(7):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[9]陈晓梅 陈巧玮 曾纪娟 张庆.可穿戴设备在慢性心力衰竭患者管理中的应用进展[J].心血管病学进展,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
　CHEN Xiaomei,CHEN Qiaowei,ZENG Jijuan,et al.Application of Wearable Devices in Management of Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(7):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
[10]李彤 呼海娟 崔炜.慢性心力衰竭患者脑钠肽抵抗机制的研究进展[J].心血管病学进展,2023,(3):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]
　LI Tong,HU Haijuan,CUI Wei.Mechanism of Brain Natriuretic Peptide Tolerance in Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(7):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]
[11]李莹洁 周闻禄 吴镜.抗阻训练对心力衰竭合并肌少症的影响及相关机制研究进展[J].心血管病学进展,2023,(11):1005.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.011]
　LI Yingjie,ZHOU Wenlu,WU Jing.Effect and Related Mechanisms of Resistance Training on Heart Failure Complicated with Sarcopenia[J].Advances in Cardiovascular Diseases,2023,(7):1005.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.011]

更新日期/Last Update: 2023-08-18